

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11462371/publications.pdf>

Version: 2024-02-01

70
papers

5,377
citations

70961

41
h-index

102304

66
g-index

70
all docs

70
docs citations

70
times ranked

3450
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1994, 88, 392-394.	1.2	455
2	Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 355-374.	1.6	449
3	Infection of peripheral mononuclear blood cells by hepatitis C virus. <i>Journal of Hepatology</i> , 1992, 15, 382-386.	1.8	418
4	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2014, 46, S165-S173.	0.4	218
5	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , 2011, 10, 444-454.	2.5	186
6	Prevalence of <i>bcl-2</i> Rearrangement in Patients with Hepatitis C Virus-Related Mixed Cryoglobulinemia with or without B-Cell Lymphomas. <i>Annals of Internal Medicine</i> , 2002, 137, 571.	2.0	185
7	Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. <i>Hepatology</i> , 2016, 64, 1473-1482.	3.6	167
8	T(14;18) translocation in chronic hepatitis C virus infection. <i>Hepatology</i> , 2000, 31, 474-479.	3.6	157
9	Hepatitis C Virus Genotype Analysis in Patients with Type II Mixed Cryoglobulinemia. <i>Annals of Internal Medicine</i> , 1996, 124, 31.	2.0	153
10	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , 2018, 4, 11.	18.1	143
11	Extrahepatic manifestations of HCV infection: facts and controversies. <i>Journal of Hepatology</i> , 1999, 31, 369-376.	1.8	140
12	Hepatitis C virus RNA localization in human carotid plaques. <i>Journal of Clinical Virology</i> , 2010, 47, 72-75.	1.6	127
13	HCV syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. <i>World Journal of Hepatology</i> , 2015, 7, 327.	0.8	118
14	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , 2010, 116, 335-342.	0.6	112
15	Hepatitis C virus-related lymphoproliferative disorders: An overview. <i>World Journal of Gastroenterology</i> , 2007, 13, 2467.	1.4	109
16	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. <i>Hepatology</i> , 2015, 61, 1145-1153.	3.6	107
17	Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. <i>Blood</i> , 2003, 102, 1196-1201.	0.6	99
18	Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. <i>Hepatology</i> , 1998, 28, 211-218.	3.6	91

#	ARTICLE	IF	CITATIONS
19	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	2.5	87
20	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	2.5	87
21	Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. <i>Journal of Medical Virology</i> , 1995, 47, 58-64.	2.5	84
22	HCV and Lymphoproliferation. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	84
23	Hepatitis C virus (HCV) infection: A systemic disease. <i>Molecular Aspects of Medicine</i> , 2008, 29, 85-95.	2.7	80
24	Extrahepatic Manifestations of Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2008, 12, 611-636.	1.0	75
25	Relation between infection and autoimmunity in mixed cryoglobulinemia. <i>Current Opinion in Rheumatology</i> , 2000, 12, 53-60.	2.0	73
26	Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 15-31.	1.3	73
27	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	1.8	73
28	A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. <i>Autoimmunity Reviews</i> , 2011, 10, 714-719.	2.5	64
29	Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. <i>Journal of Medical Virology</i> , 1997, 51, 313-318.	2.5	63
30	HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. <i>Digestive and Liver Disease</i> , 2007, 39, S55-S60.	0.4	63
31	B-cells and mixed cryoglobulinemia. <i>Autoimmunity Reviews</i> , 2007, 7, 114-120.	2.5	61
32	Cryoglobulinemia Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus. <i>American Journal of Nephrology</i> , 1993, 13, 300-304.	1.4	58
33	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , 2014, 46, 833-837.	0.4	57
34	Erectile Dysfunction and Hepatitis C Virus Infection. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 698-699.	3.8	55
35	Mixed cryoglobulinemia as a possible preneoplastic disorder. <i>Arthritis and Rheumatism</i> , 1995, 38, 1859-1860.	6.7	53
36	Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. <i>Autoimmunity Reviews</i> , 2015, 14, 889-896.	2.5	53

#	ARTICLE	IF	CITATIONS
37	Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie â€“ GISC. <i>Digestive and Liver Disease</i> , 2016, 48, 780-784.	0.4	50
38	Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virusâ€“related chronic liver disease. <i>Translational Research</i> , 1999, 134, 68-73.	2.4	47
39	â€œInapparentâ€ hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. <i>Hepatology</i> , 1994, 19, 577-582.	3.6	44
40	The hepatitis C virus infection as a systemic disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 201-208.	1.0	42
41	Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>PLoS ONE</i> , 2013, 8, e62965.	1.1	42
42	Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. <i>Journal of Autoimmunity</i> , 2015, 63, 88-93.	3.0	41
43	Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 1996, 39, 1074-1075.	6.7	36
44	Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. <i>Hepatology</i> , 2006, 43, 1166-1167.	3.6	35
45	HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation. <i>Autoimmunity Reviews</i> , 2008, 8, 107-111.	2.5	32
46	Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. <i>Journal of Hepatology</i> , 2008, 49, 170-174.	1.8	31
47	Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy. <i>Case Reports in Immunology</i> , 2015, 2015, 1-5.	0.2	28
48	Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. <i>Blood</i> , 2008, 111, 2943-2945.	0.6	24
49	Hepatitis C virus-related mixed cryoglobulinemia: Is genetics to blame?. <i>World Journal of Gastroenterology</i> , 2013, 19, 8910.	1.4	20
50	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). <i>Viruses</i> , 2021, 13, 1032.	1.5	19
51	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , 2007, 39, S129-S133.	0.4	18
52	Hepatitis C virus core protein expression in human B-cell lines does not significantly modify main proliferative and apoptosis pathways. <i>Journal of General Virology</i> , 2002, 83, 1665-1671.	1.3	18
53	Assessment of free light chains in <sc>HCV</sc>â€“positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment. <i>Liver International</i> , 2015, 35, 2100-2107.	1.9	17
54	Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	16

#	ARTICLE	IF	CITATIONS
55	Hepatitis-C virus infection and cabcer. , 1997, 71, 1113-1115.		15
56	Lymphotropic Virus Infection of Peripheral Blood Mononuclear Cells in B-Cell Non-Hodgkinâ€™s Lymphoma. Acta Haematologica, 1997, 98, 89-94.	0.7	14
57	Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. Journal of Translational Medicine, 2012, 10, 158.	1.8	14
58	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. Journal of Translational Medicine, 2014, 12, 21.	1.8	14
59	Enhanced TH1 cytokine production in hepatitis C virus-infected patients with mixed cryoglobulinemia: understanding the pathological issues. Journal of Hepatology, 2004, 41, 1045-1049.	1.8	12
60	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology, 2022, 76, 220-232.	3.6	12
61	Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. Digestive and Liver Disease, 2007, 39, S76-S82.	0.4	10
62	Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis. Antiviral Therapy, 2018, 23, 1-9.	0.6	10
63	Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. Hepatology, 2021, 74, 1164-1173.	3.6	10
64	Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. Autoimmunity Reviews, 2022, 21, 102923.	2.5	10
65	Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26b. Journal of Hepatology, 2013, 59, 1362-1363.	1.8	8
66	Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. Rheumatology, 2021, 60, 4418-4427.	0.9	4
67	B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma. Hematological Oncology, 2022, , .	0.8	4
68	The Expanding Spectrum of Clinical Features in HCV-Related Mixed Cryoglobulinemia. , 2012, , 155-162.		3
69	Editorial: interferon-free DAAs are a great boon for patients with hepatitis C and cryoglobulinaemiaâ€™ Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 772-773.	1.9	0
70	Hepatitis C Virus Lymphotropism and Possible Pathogenetic Implications.. , 1996, , 251-259.		0